Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 31-44 , February 2003

Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia

  • Jeffrey E Rubnitz

      Affiliations

    • Corresponding Author InformationCorrespondence to: Jeffrey E. Rubnitz, MD, PhD, Department of Haematology-Oncology, St. Jude Children’s Research Hospital, Mail Stop 260 332 N. Lauderdale Street, Memphis, TN 38105-2794, USA. Tel.: +1-901-495-2388; Fax: +1-901-521-9005
    • ,
  • Ching-Hon Pui

References 

  1. Pui CH, Mahmoud HH, Rivera GK, Hancock ML, Sandlund JT, Behm FG, et al.  Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukaemia. Blood. 1998;92:411–415
  2. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et al.  Improved outcome in childhood acute lymphoblastic leukaemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90 German–Austrian–Swiss ALL-BFM Study Group. Blood. 2000;95:3310–3322
  3. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al.  Improved outcome for children with acute lymphoblastic leukaemia: results of Dana–Farber consortium protocol 91-01. Blood. 2001;97:1211–1218
  4. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, Van Wering ER, et al.  BFM-oriented treatment for children with acute lymphoblastic leukaemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991–1996). Leukaemia. 2002;16:1099–1111
  5. Pui C-H, Evans WE. Acute lymphoblastic leukaemia. N. Engl. J. Med. 1998;339:605–615
  6. Pui C-H, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia – current status and future perspectives. Lancet Oncol. 2001;2:597–607
  7. Yeoh E-J, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al.  Classification, subtype discovery, and prediction of outcome in paediatric acute lymphoblastic leukaemia by gene expression profiling. Cancer Cell. 2002;1:133–143
  8. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, et al.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukaemia. Cancer Cell. 2002;1:75–87
  9. Ballerini P, Blaise A, Busson-Le Coniat M, Su XY, Zucman-Rossi J, Adam M, et al.  HOX11L2 expression defines a clinical subtype of paediatric T-ALL associated with poor prognosis. Blood. 2002;100:991–997
  10. Ribeiro RC, Broniscer A, Rivera GK, Hancock ML, Raimondi SC, Sandlund JT, et al.  Philadelphia chromosome-positive acute lymphoblastic leukaemia in children: durable responses to chemotherapy associated with low inital white blood cell counts. Leukaemia. 1997;11:1493–1496
  11. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, et al.  Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia. N. Engl. J. Med. 2000;342:998–1006
  12. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, et al.  Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359:1909–1915
  13. Heerema NA, Nachman JB, Sather HN, Sensel MG, Lee MK, Hutchinson R, et al.  Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukaemia: a report from the children’s cancer group. Blood. 1999;94:4036–4045
  14. Pui CH, Sallan S, Relling MV, Masera G, Evans WE. International childhood acute lymphoblastic leukaemia workshop: Sausalito, CA, 30 November-1 December 2000. Leukaemia. 2001;15:707–715
  15. Rubnitz JE, Downing JR, Pui CH, Shurtleff SA, Raimondi SC, Evans WE, et al.  TEL gene rearrangement in acute lymphoblastic leukaemia: a new genetic marker with prognostic significance. J. Clin. Oncol. 1997;15:1150–1157
  16. Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BA. Long-term results of treatment studies for childhood acute lymphoblastic leukaemia: paediatric oncology group studies from 1986–1994. Leukaemia. 2000;14:2276–2285
  17. Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD, et al.  Children’s cancer group trials in childhood acute lymphoblastic leukaemia: 1983–1995. Leukaemia. 2000;14:2223–2233
  18. Loh ML, Silverman LB, Young ML, Neuberg D, Golub TR, Sallan SE, et al.  Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukaemia. Blood. 1998;92:4792–4797
  19. Rubnitz JE, Behm FG, Wichlan D, Ryan C, Sandlund JT, Ribeiro RC, et al.  Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukaemia supports a favorable prognosis for this genetic subgroup. Leukaemia. 1999;13:19–21
  20. Zuna J, Hrusak O, Kalinova M, Muzikova K, Stary J, Trka J. TEL/AML1 positivity in childhood ALL: average or better prognosis?. Leukaemia. 1999;13:22–24
  21. Seeger K, Stackelberg AV, Taube T, Buchwald D, Korner G, Suttorp M, et al.  Relapse of TEL-AML1–positive acute lymphoblastic leukaemia in childhood: a matched-pair analysis. J. Clin. Oncol. 2001;19:3188–3193
  22. Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukaemia in relapse. Blood. 1997;90:4933–4937
  23. Seeger K, Adams HP, Buchwald D, Beyermann B, Kremens B, Niemeyer C, et al.  TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukaemia. The Berlin–Frankfurt–Muenster study group. Blood. 1998;91:1716–1722
  24. Ramakers-Van Woerden NL, Pieters R, Loonen AH, Hubeek I, van Drunen E, Beverloo HB, et al.  TEL/AML1 gene fusion is related to in vitro drug sensitivity for l-asparaginase in childhood acute lymphoblastic leukaemia. Blood. 2000;96:1094–1099
  25. Seeger K, Buchwald D, Taube T, Peter A, von Stackelberg A, Schmitt G, et al.  TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukaemia in childhood. Berlin–Frankfurt–Muenster study group [letter]. Leukaemia. 1999;13:1469–1470
  26. Pieters R, den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJL, et al.  Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukaemia – implications for treatment of infants. Leukaemia. 1998;12:1344–1348
  27. Kaspers GJ, Smets LA, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJ. Favorable prognosis of hyperdiploid common acute lymphoblastic leukaemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood. 1995;85:751–756
  28. Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund JT, Mahmoud H, et al.  Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukaemia. J. Clin. Invest. 1994;94:1996–2001
  29. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, et al.  Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukaemic effects in vivo. A rationale for high-dose methotrexate. J. Clin. Invest. 1996;97:73–80
  30. Ford AM, Pombo-de-Oliveira MS, McCarthy KP, MacLean JM, Carrico KC, Vincent RF, et al.  Monoclonal origin of concordant T-cell malignancy in identical twins. Blood. 1997;89:281–285
  31. Wiemels JL, Ford AM, Van Wering ER, Postma A, Greaves M. Protracted and variable latency of acute lymphoblastic leukaemia after TEL-AML1 gene fusion in utero. Blood. 1999;94:1057–1062
  32. Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G, et al.  Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;354:1499–1503
  33. Taub JW, Konrad MA, Ge Y, Naber JM, Scott JS, Matherly LH, et al.  High frequency of leukaemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukaemia. Blood. 2002;99:2992–2996
  34. Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukaemia. Proc. Natl. Acad. Sci. USA. 1998;95:4584–4588
  35. Maia AT, Ford AM, Jalali GR, Harrison CJ, Taylor GM, Eden OB, et al.  Molecular tracking of leukemogenesis in a triplet pregnancy. Blood. 2001;98:478–482
  36. Mori H, Colman SM, Xiao Z, Ford AM, Healy LE, Donaldson C, et al.  Chromosome translocations and covert leukaemic clones are generated during normal fetal development. Proc. Natl. Acad. Sci. USA. 2002;99:8242–8247
  37. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487–491
  38. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat. Rev. Cancer. 2001;1:99–108
  39. Pui C-H, Relling MV, Evans WE. Role of pharmacodynamics and pharmacogenomics in the treatment of acute lymphoblastic leukaemia. Bailliere’s Best Practices Res Clin Haematol 2002; in press
  40. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukaemia. N. Engl. J. Med. 1998;338:499–505
  41. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukaemia. Blood. 1999;93:2817–2823
  42. Relling MV, Pui CH, Sandlund JT, Rivera GK, Hancock ML, Boyett JM, et al.  Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet. 2000;356:285–290
  43. Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos. 1999;27:180–187
  44. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al.  Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 1997;126:608–614
  45. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukaemia. Leukaemia. 2000;14:567–572
  46. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. USA. 1997;94:6444–6449
  47. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin. Pharmacol. Ther. 1994;55:15–20
  48. Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology. 2000;61:136–146
  49. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer Inst. 1999;91:2001–2008
  50. Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, et al.  Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol. 2001;19:2293–2301
  51. Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG, et al.  Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukaemia. Leukaemia. 1998;12:346–352
  52. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, et al.  High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999;354:34–39
  53. Bo J, Schroder H, Kristinsson J, Madsen B, Szumlanski C, Weinshilboum R, et al.  Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer. 1999;86:1080–1086
  54. Chen CL, Liu Q, Relling MV. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics. 1996;6:187–191
  55. Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ, et al.  Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukaemia. Proc. Natl. Acad. Sci. USA. 2001;98:11592–11597
  56. Stanulla M, Schrappe M, Brechlin AM, Zimmermann M, Welte K. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukaemia: a case-control study. Blood. 2000;95:1222–1228
  57. Hall AG, Autzen P, Cattan AR, Malcolm AJ, Cole M, Kernahan J, et al.  Expression of mu class glutathione S-transferase correlates with event-free survival in childhood acute lymphoblastic leukaemia. Cancer Res. 1994;54:5251–5254
  58. Chen C-L, Liu Q, Pui C-H, Rivera GK, Sandlund JT, Ribeiro R, et al.  Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukaemia. Blood. 1997;89:1701–1707
  59. Anderer G, Schrappe M, Brechlin AM, Lauten M, Muti P, Welte K, et al.  Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics. 2000;10:715–726
  60. Davies SM, Bhatia S, Ross JA, Kiffmeyer WR, Gaynon PS, Radloff GA, et al.  Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukaemia. Blood. 2002;100:67–71
  61. Brenner TL, Pui CH, Evan WE. Pharmacogenomics of childhood acute lymphoblastic leukaemia. Curr. Opin. Mol. Ther. 2001;3:567–578
  62. Davies SM, Robison LL, Buckley JD, Tjoa T, Woods WG, Radloff GA, et al.  Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukaemia. J. Clin. Oncol. 2001;19:1279–1287
  63. Naoe T, Tagawa Y, Kiyoi H, Kodera Y, Miyawaki S, Asou N, et al.  Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukaemia: increased early death after chemotherapy. Leukaemia. 2002;16:203–208
  64. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to childhood acute lymphoblastic leukaemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood. 1999;93:1496–1501
  65. Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M, et al.  Adenoviral E1A-associated protein p300 is involved in acute myeloid leukaemia with t(11;22)(q23;q13). Blood. 1997;90:4699–4704
  66. Woo MH, Shuster JJ, Chen C, Bash RO, Behm FG, Camitta B, et al.  Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukaemia. 2000;14:232–237
  67. Danesi R, De Braud F, Fogli S, Di Paolo A, Del Tacca M. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol. Sci. 2001;22:420–426
  68. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 2001;27:383–391
  69. Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, et al.  Association of CYP3A4 genotype with treatment-related leukaemia. Proc. Natl. Acad. Sci. USA. 1998;95:13176–13181
  70. Krajinovic M, Labuda D, Mathonnet G, Labuda M, Moghrabi A, Champagne J, et al.  Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukaemia. Clin. Cancer Res. 2002;8:802–810
  71. Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukaemia. Int. J. Cancer. 2002;97:230–236
  72. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995;10:111–113
  73. Molloy AM, Daly S, Mills JL, Kirke PN, Whitehead AS, Ramsbottom D, et al.  Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet. 1997;349:1591–1593
  74. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al.  A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am. J. Hum. Genet. 1998;62:1044–1051
  75. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J. Rheumatol. 1998;25:441–446
  76. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, et al.  Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001;98:231–234
  77. Thompson JR, Gerald PF, Willoughby ML, Armstrong BK. Maternal folate supplementation in pregnancy and protection against acute lymphoblastic leukaemia in childhood: a case-control study. Lancet. 2001;358:1935–1940
  78. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, et al.  Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukaemia in adults. Proc. Natl. Acad. Sci. USA. 1999;96:12810–12815
  79. Franco RF, Simoes BP, Tone LG, Gabellini SM, Zago MA, Falcao RP. The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia. Br. J. Haematol. 2001;115:616–618
  80. Wiemels JL, Smith RN, Taylor GM, Eden OB, Alexander FE, Greaves MF. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukaemia. Proc. Natl. Acad. Sci. USA. 2001;98:4004–4009
  81. Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves MF. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with paediatric leukaemias that have MLL fusions United Kingdom childhood cancer study investigators. Cancer Res. 1999;59:4095–4099
  82. Smith MT, Wang Y, Kane E, Rollinson S, Wiemels JL, Roman E, et al.  Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukaemia in adults. Blood. 2001;97:1422–1426
  83. Larson RA, Wang Y, Banerjee M, Wiemels J, Hartford C, Le Beau MM, et al.  Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukaemia. Blood. 1999;94:803–807
  84. Naoe T, Takeyama K, Yokozawa T, Kiyoi H, Seto M, Uike N, et al.  Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukaemia/myelodysplastic syndrome and de novo acute myeloid leukaemia. Clin. Cancer Res. 2000;6:4091–4095
  85. Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet. 2002;359:1033–1034
  86. Skibola CF, Smith MT, Hubbard A, Shane B, Roberts AC, Law GR, et al.  Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukaemia. Blood. 2002;99:3786–3791
  87. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer. 2002;2:48–58
  88. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, et al.  Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukaemia in childhood (therapy study ALL-BFM 83). Klin. Padiatr. 1987;199:151–160
  89. Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT, et al.  Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukaemia. Blood. 1995;86:1292–1295
  90. Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, Conter V, et al.  Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukaemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood. 1998;92:2730–2741
  91. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S, et al.  Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukaemia. Blood. 1999;94:1209–1217
  92. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, et al.  Cytoreduction and prognosis in acute lymphoblastic leukaemia – the importance of early marrow response: report from the children’s cancer group. J. Clin. Oncol. 1996;14:389–398
  93. Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, et al.  Early response to therapy and outcome in childhood acute lymphoblastic leukaemia: a review. Cancer. 1997;80:1717–1726
  94. Pui CH. Risk assessment in acute lymphoblastic leukaemia: beyond leukaemia cell characteristics. J. Pediatr. Hematol. Oncol. 2001;23:405–408
  95. Sandlund JT, Harrison PL, Rivera G, Behm FG, Head D, Boyett J, et al.  Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukaemia. Blood. 2002;100:43–47
  96. Campana D, Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract. Res. Clin. Haematol. 2002;15:1–19
  97. Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukaemia. Leukaemia. 2000;14:783–785
  98. Szczepanski T, Orfao A, van DVV, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol. 2001;2:409–417
  99. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, et al.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351:550–554
  100. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukaemia. Blood. 2000;96:2691–2696
  101. Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC, et al.  Prognostic importance of measuring early clearance of leukaemic cells by flow cytometry in childhood acute lymphoblastic leukaemia. Blood. 2002;100:52–58
  102. Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, et al.  Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukaemia. Blood. 2002;100:2399–2402
  103. Neale GA, Coustan-Smith E, Pan Q, Chen X, Gruhn B, Stow P, et al.  Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukaemia. Leukaemia. 1999;13:1221–1226
  104. Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N, et al.  Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukaemia. Blood. 2002;99:1952–1958
  105. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukaemia. Blood. 2000;96:24–33
  106. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, et al.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukaemia. Nat. Genet. 2002;30:41–47
  107. Silverman LB, McLean TW, Gelber RD, Donnelly MJ, Gilliland DG, Tarbell NJ, et al.  Intensified therapy for infants with acute lymphoblastic leukaemia: results from the Dana–Farber cancer institute consortium. Cancer. 1997;80:2285–2295
  108. Chessells JM, Harrison CJ, Watson SL, Vora AJ, Richards SM. Treatment of infants with lymphoblastic leukaemia: results of the UK infant protocols 1987–1999. Br. J. Haematol. 2002;117:306–314
  109. Isoyama K, Eguchi M, Hibi S, Kinukawa N, Ohkawa H, Kawasaki H, et al.  Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan infant leukaemia study (MLL96). Br. J. Haematol. 2002;118:999–1010
  110. Pui C-H, Boyett JM, Relling MV, Harrison PL, Rivera GK, Behm FG, et al.  Sex differences in prognosis for children with acute lymphoblastic leukaemia. J. Clin. Oncol. 1999;17:818–824
  111. Shuster JJ, Wacker P, Pullen J, Humbert J, Land VJ, Mahoney DHJ, et al.  Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukaemia: a paediatric oncology group study. J. Clin. Oncol. 1998;16:2854–2863
  112. Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynon PS, Robison LL. Racial and ethnic differences in survival of children with acute lymphoblastic leukaemia. Blood. 2002;100:1957–1964
  113. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, et al.  Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin–Frankfurt–Muenster. Leukaemia. 2000;14:2205–2222
  114. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukaemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukaemia. 2000;14:2234–2239
  115. Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD, et al.  Results of Dana–Farber cancer institute consortium protocols for children with newly diagnosed acute lymphoblastic leukaemia (1981–1995). Leukaemia. 2000;14:2247–2256
  116. Kamps WA, Veerman AJ, Van Wering ER, van Weerden JF, Slater R, Does-van den Berg A. Long-term follow-up of dutch childhood leukaemia study group (DCLSG) protocols for children with acute lymphoblastic leukaemia, 1984–1991. Leukaemia. 2000;14:2240–2246
  117. Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM, et al.  Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukaemia. Cancer. 2000;88:1964–1969
  118. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, et al.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukaemia and a slow response to initial therapy. N. Engl. J. Med. 1998;338:1663–1671
  119. Lange BJ, Bostrom BC, Cherlow JM, Sensel MG, La MK, Rackoff W, et al.  Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukaemia: a report from the children’s cancer group. Blood. 2002;99:825–833
  120. Arico M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C, et al.  Improved outcome in high-risk childhood acute lymphoblastic leukaemia defined by prednisone-poor response treated with double Berlin–Frankfurt–Muenster protocol II. Blood. 2002;100:420–426
  121. Chessells JM, Harrison G, Richards SM, Gibson BE, Bailey CC, Hill FG, et al.  Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. Br. J. Haematol. 2002;118:445–455
  122. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, et al.  Intensive high-dose asparaginase consolidation improves survival for paediatric patients with T cell acute lymphoblastic leukaemia and advanced stage lymphoblastic lymphoma: a paediatric oncology group study. Leukaemia. 1999;13:335–342
  123. McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J, et al.  TEL/AML1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukaemia. Blood. 1996;88:4252–4258
  124. Lipshultz SE, Giantris AL, Lipsitz SR, Kimball DV, Asselin BL, Barr RD, et al.  Doxorubicin administration by continuous infusion is not cardioprotective: the Dana–Farber 91-01 acute lymphoblastic leukaemia protocol. J. Clin. Oncol. 2002;20:1677–1682
  125. Toyoda Y, Manabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y, et al.  Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukaemia of childhood. J. Clin. Oncol. 2000;18:1508–1516
  126. Chessells JM, Harrison G, Lilleyman JS, Bailey CC, Richards SM. Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical research council working party in childhood leukaemia. Br. J. Haematol. 1997;98:945–951
  127. Dervieux T, Medard Y, Verpillat P, Guigonis V, Duval M, Lescoeur B, et al.  Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukaemia with mercaptopurine. Leukaemia. 2001;15:1706–1712
  128. Fuscoe JC, Knapp GW, Hanley NM, Setzer RW, Sandlund JT, Pui CH, et al.  The frequency of illegitimate V(D)J recombinase-mediated mutations in children treated with etoposide-containing antileukaemic therapy. Mutat. Res. 1998;419:107–121
  129. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12,000 randomised children. Childhood ALL Collaborative Group. Lancet 1996;347:1783–1788
  130. Mattano LA, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukaemia in children: a report from the children’s cancer group. J. Clin. Oncol. 2000;18:3262–3272
  131. Ribeiro RC, Fletcher BD, Kennedy W, Harrison PL, Neel MD, Kaste SC, et al.  Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukaemia or non-Hodgkin lymphoma. Leukaemia. 2001;15:891–897
  132. Strauss AJ, Su JT, Dalton VM, Gelber RD, Sallan SE, Silverman LB. Bony morbidity in children treated for acute lymphoblastic leukaemia. J. Clin. Oncol. 2001;19:3066–3072
  133. Pui C-H. Childhood leukaemias. N. Engl. J. Med. 1995;332:1618–1630
  134. Gajjar A, Harrison PL, Sandlund JT, Rivera GK, Ribeiro RC, Rubnitz JE, et al.  Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukaemia. Blood. 2000;96:3381–3384
  135. Eden OB, Harrison G, Richards S, Lilleyman JS, Bailey CC, Chessells JM, et al.  Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980–1997. Medical research council childhood leukaemia working party. Leukaemia. 2000;14:2307–2320
  136. Walter AW, Hancock ML, Pui CH, Hudson MM, Ochs JS, Rivera GK, et al.  Secondary brain tumors in children treated for acute lymphoblastic leukaemia at St. Jude children’s research hospital. J. Clin. Oncol. 1998;16:3761–3767
  137. Bhatia S, Sather HN, Pabustan OB, Trigg ME, Gaynon PS, Robison LL. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukaemia after 1983. Blood. 2002;99:4257–4264
  138. Pui C-H. Cure of childhood ALL: exacting a lower toll. Blood. 2002;99:4255
  139. Manera R, Ramirez I, Mullins J, Pinkel D. Pilot studies of species-specific chemotherapy of childhood acute lymphoblastic leukaemia using genotype and immunophenotype. Leukaemia. 2000;14:1354–1361
  140. Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave H, Thyss A, et al.  Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukaemia: a CLCG-EORTC report. Children leukaemia cooperative group. Leukaemia. 2000;14:2257–2266
  141. Leung W, Rose SR, Zhou Y, Hancock ML, Burstein S, Schriock EA, et al.  Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukaemia. J. Clin. Oncol. 2002;20:2959–2964
  142. Pui C-H. Toward optimal central-nervous-system treatment in childhood ALL. J Clin Oncol 2002; in press
  143. Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG, et al.  Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukaemia. N. Engl. J. Med. 1993;329:314–319
  144. Lauer S, Shuster J, Kirchner P, Kiefer G, Pullen J, Camitta B, et al.  Prognostic significance of cerebrospinal fluid (CSF) lymphoblasts (LB) at diagnosis (dx) in children with acute lymphoblastic leukaemia (ALL) (Meeting abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1994;13:317
  145. Gilchrist GS, Tubergen DG, Sather HN, Coccia PF, O’Brien RT, Waskerwitz MJ, et al.  Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukaemia in children with intermediate-risk acute lymphoblastic leukaemia: a children’s cancer group report. J. Clin. Oncol. 1994;12:2594–2600
  146. van den BH, Vet R, den Ouden E, Behrendt H. Significance of lymphoblasts in cerebrospinal fluid in newly diagnosed paediatric acute lymphoblastic malignancies with bone marrow involvement: possible benefit of dexamethasone. Med. Pediatr. Oncol. 1995;25:22–27
  147. Burger B, Zimmermann M, Mann G, Kuhl J, Loning L, Riehm H, et al. Diagnostic cerebrospinal fluid (CSF) examination in children with acute lymphoblastic leukaemia (ALL): significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2002; in press
  148. Nachman J, Cherlow J, Sather HN. Effect of initial central nervous system (CNS) status on event-free (EFS) in children and adolescents with acute lymphoblastic leukaemia (ALL). Med. Pediatr. Oncol. 2002;39:277; (abstract)
  149. Prassopoulos P, Cavouras D, Golfinopoulos S, Evlogias N, Theodoropoulos V, Panagiotou J. Quantitative assessment of cerebral atrophy during and after treatment in children with acute lymphoblastic leukaemia. Invest. Radiol. 1996;31:749–754
  150. Vainionpaa L, Kovala T, Tolonen U, Lanning M. Chemotherapy for acute lymphoblastic leukaemia may cause subtle changes of the spinal cord detectable by somatosensory evoked potentials. Med. Pediatr. Oncol. 1997;28:41–47
  151. Hill DE, Ciesielski KT, Sethre-Hofstad L, Duncan MH, Lorenzi M. Visual and verbal short-term memory deficits in childhood leukaemia survivors after intrathecal chemotherapy. J. Pediatr. Psychol. 1997;22:861–870
  152. Howard SC, Gajjar A, Cheng C, Kritchevsky SB, Somes GW, Harrison PL, et al. Traumatic lumbar puncture in childhood acute lymphoblastic leukaemia. J Am Med Assoc 2002; in press
  153. Howard SC, Gajjar A, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, et al.  Safety of lumbar puncture for children with acute lymphoblastic leukaemia and thrombocytopenia. J. Am. Med. Assoc. 2000;284:2222–2224
  154. Pui CH, Jackson CW, Chesney C, Lyles SA, Bowman WP, Abromowitch M, et al.  Sequential changes in platelet function and coagulation in leukaemic children treated with l-asparaginase, prednisone, and vincristine. J. Clin. Oncol. 1983;1:380–385
  155. Marie JP. Drug resistance in haematologic malignancies. Curr. Opin. Oncol. 2001;13:463–469
  156. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001;7:1028–1034
  157. Sorrentino BP. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat. Rev. Cancer. 2002;2:431–441
  158. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N. Engl. J. Med. 2001;344:1031–1037
  159. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al.  Haematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. N. Engl. J. Med. 2002;346:645–652
  160. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al.  Imatinib induces durable haematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukaemia: results of a phase 2 study. Blood. 2002;99:1928–1937
  161. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al.  Imatinib induces haematologic and cytogenetic responses in patients with chronic myelogenous leukaemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530–3539
  162. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukaemia with the Philadelphia chromosome. N. Engl. J. Med. 2001;344:1038–1042
  163. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, et al.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukaemias. Blood. 2002;100:1965–1971
  164. Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, et al.  Inhibition of mutant FLT3 receptors in leukaemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1:433–443
  165. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, et al.  CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukaemia (AML). Cancer Cell. 2002;1:421–432
  166. Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, et al.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukaemia cells in vitro and in vivo. Blood. 2002;99:3885–3891

PII: S0305-7372(02)00106-8

doi: 10.1016/S0305-7372(02)00106-8

Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 31-44 , February 2003

Article Tools